The U.S. Food and Drug Administration (FDA) has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, which could be a lifesaver for people dealing with the disease who are
FDA approves groundbreaking cell-based gene therapies for Sickle Cell Disease northdallasgazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from northdallasgazette.com Daily Mail and Mail on Sunday newspapers.
Sickle cell disease, a group of inherited blood disorders, affects around 100,000 individuals in the United States and is predominant among African Americans.
The U.S. Food and Drug Administration (FDA) approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.